Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

por Kaseb, Ahmed O, Morris, Jeffrey S, Iwasaki, Michiko, Al-Shamsi, Humaid O, Raghav, Kanwal Pratap Singh, Girard, Lauren, Cheung, Sheree, Nguyen, Van, Elsayes, Khaled M, Xiao, Lianchun, Abdel-Wahab, Reham, Shalaby, Ahmed S, Hassan, Manal, Hassabo, Hesham M, Wolff, Robert A, Yao, James C
Publicado 2016